【个人简介】
朱爱如，博士，南山学者骨干人才特聘教授，广东省特支青年拔尖人才。本硕毕业于四川大学，2021年博士毕业于广州医科大学内科学专业，2021年-2025年于广州医科大学附属第一医院/呼吸疾病全国重点实验室从事博士后研究工作，2025年全职加入广州医科大学附属第一医院/广州呼吸健康研究院/呼吸疾病全国重点实验室工作。长期聚焦呼吸道病毒感染与疫苗接种人群的黏膜免疫与外周免疫机制研究，主要研究成果包括揭示呼吸道黏膜T细胞在新冠病毒清除中的核心作用，阐明其与外周T细胞的差异特征，发现肌注疫苗难以诱导黏膜记忆。通过MERS-CoV特异性T细胞应答首次证实非洲单峰驼密接人群存在隐匿感染，揭示动物-人跨种传播链，指导MERS监测，填补重要病原体传播机制空白。构建新冠、MERS及低冠（229E/NL63）小鼠模型等动物模型，参与制定《新冠病毒抗原特异性T细胞检测专家共识》，推动疫苗药物评价标准化。近5年以第一/通讯作者（含共同）发表论文21篇，10篇IF>10，包括Nat Immunol（2025, 2024）、Nat Commun(2025)、Lancet Infect Dis（2021）、Cell（2020）、STTT（2023a, b）、PNAS（2023）、Emerg Microbes Infect（2020）、Adv Sci （2023）、Cell Discov（2024）等。
【研究方向】
呼吸系统感染免疫；黏膜免疫；疫苗评价
【科研项目】
1. 国家自然科学基金委员会，面上项目，82670022，内因子自身抗体介导的VB12缺乏加重呼吸道病毒感染的免疫调控机制研究，2027.01-2030.12，60万元，在研，主持
2. 国家自然科学基金委员会，重大研究计划培育项目，92569105，新冠病毒感染与鼻喷疫苗免疫人群上呼吸道免疫应答动态规律研究，2026.01.01-2028.12.31，60万元，在研，主持
3. 广东省基础与应用基础研究基金项目，区域联合基金-地区培育项目，2025A1515140026，腺病毒载体疫苗经鼻免疫诱导的人群呼吸道黏膜免疫应答特征与规律研究，2025.11.01-2028.10.31，30万元，在研，主持
4. 国家自然科学基金委员会，青年科学基金项目，82201933，肺内新冠病毒特异性T细胞应答在疾病转归中的作用及机制研究，2023-01-01 至 2025-12-31，30万元，结题，主持
【代表性论文及著作】
1. Mok CKP#, Zhu A#, Oladipo JO, Bai H, Cheng SMS, Kuranga SA, Lv H, Zhao J*, Peiris M*. Middle East Respiratory Syndrome Coronavirus-Specific T-Cell Responses in Dromedary Camel Abattoir Workers in Nigeria Suggests Frequent Zoonotic Spillover. J Infect Dis. 2026;233(6):1058-1062. (IF=4.17)
2. Wang Y#, Cai R#, Zhu A#, Chen J, Chen C, Zhou L, Xing X, Zhong Q, Wei P, Li X, Zhang Z, Zhang Y, Chen L, Gao J, Li S, Xiong X, Qu B, Huang S, Lin Z, Bai H, Hu Q, Zhao J, Shi Y, Yang Y, Qin P, Zhang L, Zhao J. Immune profiling of mpox survivors reveals divergent durability of antibody and T cell responses. Nat Commun. 2025;17(1):570. Published 2025 Dec 4. (IF=18.1)
3. Zhang J#, Zhu A#, Wei S, Shi Y, Chen C, Huang T, Tang T, Zhao J, Cai Y, Han C, Zhao J, Wang Y. Identification of Pan-Coronavirus Neutralizing Aptamers Through CRISmers Targeting the Conserved Fusion Peptide. Adv Healthc Mater. 2025 Aug;14(21):e2501869. （IF=11.0）
4. Chen L, Zhang S, Chen Z, Cheng J, Chen C, Tang T, Zhao J, Zhao J, Zhong N, Zhang N, Zhu A*. Impact of obstructive sleep apnea severity and treatment on COVID-19 vaccine-induced immune responses. J Thorac Dis. 2025 Aug 31;17(8):5610-5625. (IF=2.3)
5. Zhu A#, Chen Z#, Yan Q#, Jiang M#, Liu X#, Li Z#, Li N#, Tang C#, Jian W#, He J, Chen L, Cheng J, Chen C, Tang T, Xu Z, Hu Q, Li F, Wang Y, Sun J, Zhuang Z, Wen L, Zhuo J, Liu D, Zhang Y, Huang X, Li S, Zeng Q, Chen F, Zhou L, Liu D, Zhong C, Chen Y, Li S, Liang K, Zhong N, Zhang X, Chen J, Chen X*, Xu Y*, Zhong N*, Zhao J*, Zhao J*. Robust mucosal SARS-CoV-2-specific T cells effectively combat COVID-19 and establish polyfunctional resident memory in patient lungs. Nat Immunol. 2025 Mar;26(3):459-472. (IF=26.5)
6. Chen C#, Tang T#, Chen Z#, Chen L, Cheng J, Li F, Sun J, Zhao J, Wang Y, Yan Q*, Zhao J*, Zhu A*. Antibody dynamics for heterologous boosters with aerosolized Ad5-nCoV following inactivated COVID-19 vaccines. Hum Vaccin Immunother. 2024 Dec 31;20(1):2423466. (IF=4.2)
7. Zhu A#, Zhou L#, Chen Z, Liu D, Feng H, Cai B, Chen X, Zhao J, Zhao J, Chen J, Li M*, He J*. Single-cell analysis reveals T cell dysfunction driven by macrophages and differential expression of transposable elements in severe COVID-19 patients. Heliyon. 2024 Sep 27;10(19):e38688. (IF=3.4)
8. Chen Z#, Yuan Y#, Hu Q#, Zhu A#, Chen F, Li S, Guan X, Lv C, Tang T, He Y, Cheng J, Zheng J, Hu X, Zhao J*, Zhao J*, Sun J*. SARS-CoV-2 immunity in animal models. Cell Mol Immunol. 2024 Feb;21(2):119-133. (IF=21.8)
9. Zhao H#, Zhang NN#, Hannawi S#, Zhu AR#, Xiong XC, Huang YJ, Yu DD, Chen CJ, Dai J, Abuquta A, Ying B*, Zhao JC*, Qin CF*. Neutralization of Omicron XBB.1 by booster vaccination with BA.4/5 monovalent mRNA vaccine. Cell Discov. 2024 Jan 9;10(1):7. (IF=16.9)
10. Zhang J#, Zhu A#, Mei M, Qu J, Huang Y, Shi Y, Xue M, Zhang J, Zhang R*, Zhou B*, Tan X*, Zhao J*, Wang Y*. Repurposing CRISPR/Cas to Discover SARS-CoV-2 Detecting and Neutralizing Aptamers. Adv Sci (Weinh). 2023 Aug;10(22):e2300656. (IF=14.1)
11. Zhu A#, Wei P#, Man M#, Liu X#, Ji T#, Chen J, Chen C, Huo J*, Wang Y*, Zhao J*. Antigenic characterization of SARS-CoV-2 Omicron subvariants XBB.1.5, BQ.1, BQ.1.1, BF.7 and BA.2.75.2. Signal Transduct Target Ther. 2023 Mar 15;8(1):125. (IF=81.2)
12. Qiu S#, Chen Z#, Zhu A#, Zeng Q#, Liu H#, Liu X, Ye F, Jin Y, Wu J, Yang C, Wang Q, Chen F, Chen L, Tian S, Du X, Hu Q, Cheng J, Chen C, Li F, Sun J, Wang Y, Zhao J*, Zhao J*, Song H*. Successful clearance of persistent SARS-CoV-2 asymptomatic infection following a single dose of Ad5-nCoV vaccine. Signal Transduct Target Ther. 2023 Mar 15;8(1):123. (IF=81.2)
13. Liu D#, Chen C#, Chen D#, Zhu A#, Li F#, Zhuang Z, Mok CKP, Dai J, Li X, Jin Y, Chen Z, Sun J, Wang Y, Li Y, Zhang Y, Wen L, Zhang Z, Zhuo J, Wang J, Ran W, Wang D, Zhang S, Tang Y, Li S, Lai X, Wei P, Yuan J, Chen F, Huang S, Sun F, Qian Z, Tan W, Zhao J*, Peiris M*, Zhao J*. Mouse models susceptible to HCoV-229E and HCoV-NL63 and cross protection from challenge with SARS-CoV-2. Proc Natl Acad Sci U S A. 2023 Jan 24;120(4):e2202820120. (IF=9.5)
14. Mok CKP#, Zhu A#, Zhao J#, Lau EHY, Wang J, Chen Z, Zhuang Z, Wang Y, Alshukairi AN, Baharoon SA, Wang W, Tan W, Liang W, Oladipo JO, Perera RAPM, Kuranga SA, Peiris M*, Zhao J*. T-cell responses to MERS coronavirus infection in people with occupational exposure to dromedary camels in Nigeria: an observational cohort study. Lancet Infect Dis. 2021 Mar;21(3):385-395. (IF=29.4)
15. Sun J#, Zhu A#, Li H#, Zheng K#, Zhuang Z#, Chen Z#, Shi Y#, Zhang Z#, Chen SB#, Liu X#, Dai J, Li X, Huang S, Huang X, Luo L, Wen L, Zhuo J, Li Y, Wang Y, Zhang L, Zhang Y, Li F, Feng L, Chen X, Zhong N, Yang Z*, Huang J*, Zhao J*, Li YM*. Isolation of Infectious SARS-CoV-2 from Urine of a COVID-19 Patient. Emerg Microbes Infect. 2020 Apr 28:1-8. (IF=7.0)
16. Airu Zhu#, Zhao Chen, Yanqun Wang, Qiuhui Zeng, Jing Sun, Zhen Zhuang, Fang Li, Jingxian Zhao, Jincun Zhao*, Nanshan Zhong*, Immune responses to SARS-CoV-2 infection in Humans and ACE2 humanized mice. Fundamental Research 1 (2021) 124–130.
【所获荣誉和奖励】
1.2025年获“广东特支计划·青年拔尖人才”称号
